Humankind Investments LLC Has $2.29 Million Holdings in Abbott Laboratories $ABT

Humankind Investments LLC raised its holdings in Abbott Laboratories (NYSE:ABT) by 32.5% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 16,808 shares of the healthcare product maker’s stock after buying an additional 4,126 shares during the period. Abbott Laboratories comprises approximately 0.6% of Humankind Investments LLC’s investment portfolio, making the stock its 27th biggest holding. Humankind Investments LLC’s holdings in Abbott Laboratories were worth $2,286,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Avanza Fonder AB lifted its holdings in shares of Abbott Laboratories by 0.4% during the second quarter. Avanza Fonder AB now owns 168,401 shares of the healthcare product maker’s stock worth $22,904,000 after buying an additional 655 shares in the last quarter. Seaview Investment Managers LLC bought a new position in Abbott Laboratories during the second quarter worth about $11,068,000. Guggenheim Capital LLC raised its stake in Abbott Laboratories by 13.5% in the 2nd quarter. Guggenheim Capital LLC now owns 98,941 shares of the healthcare product maker’s stock worth $13,457,000 after purchasing an additional 11,794 shares in the last quarter. Atria Investments Inc boosted its holdings in Abbott Laboratories by 8.3% in the 2nd quarter. Atria Investments Inc now owns 184,269 shares of the healthcare product maker’s stock valued at $25,062,000 after purchasing an additional 14,185 shares during the period. Finally, Financial Management Professionals Inc. increased its holdings in shares of Abbott Laboratories by 715.7% during the second quarter. Financial Management Professionals Inc. now owns 6,142 shares of the healthcare product maker’s stock worth $835,000 after purchasing an additional 5,389 shares during the period. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Stock Up 1.8%

ABT stock opened at $125.47 on Friday. The firm has a 50-day moving average price of $127.45 and a 200-day moving average price of $130.49. Abbott Laboratories has a 12 month low of $110.86 and a 12 month high of $141.23. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $218.17 billion, a P/E ratio of 15.72, a price-to-earnings-growth ratio of 2.25 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.30. The business had revenue of $11.37 billion during the quarter, compared to analysts’ expectations of $11.40 billion. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.60%. The firm’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same period in the prior year, the company earned $1.21 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. As a group, equities research analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, November 17th. Investors of record on Wednesday, October 15th were issued a dividend of $0.59 per share. The ex-dividend date of this dividend was Wednesday, October 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.9%. Abbott Laboratories’s dividend payout ratio (DPR) is 29.57%.

Analyst Ratings Changes

A number of brokerages recently issued reports on ABT. Raymond James Financial increased their price target on Abbott Laboratories from $141.00 to $146.00 and gave the stock an “outperform” rating in a research report on Thursday, October 16th. Mizuho increased their target price on Abbott Laboratories from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday, October 14th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Abbott Laboratories in a research report on Monday. William Blair raised shares of Abbott Laboratories to a “strong-buy” rating in a report on Thursday, November 20th. Finally, Benchmark assumed coverage on shares of Abbott Laboratories in a report on Friday, October 10th. They set a “buy” rating and a $145.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $147.00.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.